This Biotech with Breakout MS Drug Draws Big Investment
A breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Choosing between Sp500 and Total Market funds can shape your retirement. This guide compares performance, diversification, and allocation to help you decide.
28,514 articlesA breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Gary Keller argues that a data-driven view can outweigh market gloom, foreseeing 4.3 million home sales in 2026 and a...
Palantir has seen a sizable pullback, but the real question for patient AI investors is whether this move creates a d...
Strategy Inc. raised hundreds of millions by selling new common stock to buy bitcoin, while Michael Saylor posted a r...
The SpaceX IPO dominates chatter, but you don’t have to wait to gain space exposure. Here are three space stocks with...
Brookfield is quietly expanding its private debt platform, aiming to become a major player in private credit. This ar...
PayPal faces a tough stretch in the public eye, yet cash flow and a disciplined capital plan hint at upside. Here’s w...
SpaceX embodies big dreams and bigger valuations. This piece digs into Morningstar's fair value for Spacex, why the m...
Planning a summer move in Houston? This practical guide shows how to spot bait-and-switch scams, verify movers, and p...
SpaceX faces a towering IPO target: a $1.5 trillion market cap. Analysts say the math hinges on unprecedented growth ...
As AI stocks surge, Wall Street may signal overvaluation. I break down the arguments, share why I disagree, and give ...
A trio of high-yield names—PNNT, GLAD, and KRP—show divergent payout reliability even as yields approach double digit...